Time BioVentures

The firm has not publicly disclosed its managing partners, managing directors, or investment committee members. For a life-sciences venture firm, where investor track record and scientific network heavily influence deal access and LP confidence, this absence is notable. Prospective co-investors and allocators may need to establish direct contact to assess the relevant experience and decision-making structure.

Time BioVentures covers a wide spectrum including seed, startup, early-stage, and growth-stage companies, as well as what it terms 'complex situations.' In biotech, complex situations often refer to corporate spinouts, asset-level financings, restructurings, or companies navigating difficult clinical or regulatory transitions. The firm's venture general mandate suggests it may also make opportunistic investments outside its core thesis.

The firm maintains offices in both the US and Europe, including New York, San Francisco, Los Angeles, London, and Paris. This transatlantic footprint positions it to source from leading academic and biotech clusters on both continents. Without detailed portfolio data, the relative balance of US versus European deployment is unclear.

No. Time BioVentures has not publicly disclosed assets under management, fund size, or aggregate deployment. In a sector where fund size signals capacity to support capital-intensive clinical trials, the lack of disclosure may reflect a lean fund structure, a concentration of capital from a small LP group, or a deliberate low-profile strategy.

No explicit sector exclusions are publicly stated. The firm's focus appears firmly within biotechnology, life sciences, and healthcare, with no indication of activity in software, consumer tech, or industrial sectors. Allocators should assume a mandate concentrated on therapeutics, platforms, tools, and health services unless the firm's own materials clarify otherwise.